Publications by authors named "L Jelti"
Background: Following the RITUX 3 therapeutic trial, the French national diagnosis and care protocol (NDCP) for the treatment of pemphigus was updated in 2018. The updated protocol recommends initial treatment with rituximab (RTX) followed by maintenance therapy at 12 and 18 months, and potentially at 6 months where there are risk factors for early relapse. We evaluated these recommendations regarding the management of our own patients.
View Article and Find Full Text PDFArticle Synopsis
- Bullous pemphigoid (BP) is a common autoimmune blistering disorder with varied clinical presentations, which this study aimed to explore in detail.
- Researchers analyzed data from BP patients at two centers over a six-year period, using clustering methods to identify different profiles.
- They discovered three distinct clusters of patients, highlighting significant differences in age, clinical features, antibody presence, and severity, with one cluster related to a more severe form of the disease resembling mucous membrane pemphigoid.
Pruritus is a common symptom of bullous pemphigoid (BP), but has been poorly studied. The aim of this study was to analyse the characteristics of pruritus in patients with BP and its impact on their quality of life. A multicentre prospective observational study (in 15 French hospitals) was performed.
View Article and Find Full Text PDF